Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease;Ezetimib/simvastatin kombinált terápia biztonsá gossága és hatékonysága 2-es típusú diabeteses, nem alkoholos zsírmájú betegekben

Orvosi Hetilap

Volumn 150, Issue 21, 2009, Pages 989-993

  Ábel, Tatjána ^a,e   Fehér, János ^b   Dinya, Elek ^c   Gamal Eldin, Mohamed ^d   Kovács, Attila ^d  

^a Allami Egeszsegugyi Kozpont State Health Center   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c EGIS PHARMACEUTICALS LTD   (Hungary)

^d Budaörsi Egészségügyi Központ   (Hungary)

^e NONE   (Hungary)

Author keywords

Cardiovascular risk; Fatty liver; Hyperlipidemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 66149132171     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28624     Document Type: Article

References (25)

1. Preiss, D., Sattar, N.: Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis pathogenesis and treatment considerations. Clin. Science, 2008, 115, 141-150.
2. Targher, G., Bertolini, L., Padovani, R. és mtsai: Increased prevalence of cardiovascular disease among type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet. Med., 2006, 23, 403-409.
3. Pasternak, R. C., Smith, S. C., Bariey-Merz, C. N. és mtsai: ACC/ AHA/NHLBI Clinical Advisory on the Use and Safety of Satins. Circulation, 2002, 106, 1024-1028.
4. Bays, H.: Ezetimibe. Expert Opin Invest. Drugs, 2002, 11, 1587-1604.
5. Kosoglou, T., Meyer, I., Veltri E. P. és mtsai: Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br. J. Clin. Pharmacol., 2002, 54, 309-319.
6. Hildemann, S. K., Barho, C., Karmann, B. és mtsai: Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hyper-cholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr. Med. Res. Opin., 2007, 23, 713-719.
7. Ahmed, M. H., Saad, R. A., Osman, M. M.: Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Expert Opin Drug. Saf., 2006, 5, 487- 488.
8. Yamagashi, S., Nakamura, K., Matsui, T. és mtsai: Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med. Hypothesis, 2006, 66, 844- 846.
9. Liberopoulos, E. N., Athyros, V. G., Elisaf, M. S. és mtsa: Statins for non-alcoholic fatty liver disease: a new indication? Aliment. Pharmacol. Ther., 2006, 24, 698-699.
10. Argo, C. K., Loria, P., Caldwell, S. H. és mtsa: Statins in liver disease: a molehill, an iceberg, or neither? Hepatology, 2008, 48, 662-669.
11. Vuppalanchi, R., Chalasani N.: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology, 2009, 49, 306-317.
12. Florentin, M., Liberopoulos, E. N., Elisaf, M. S.: Ezetimibe-associ-ated adverse effects: what the clinican needs to know. Clin. Pract., 2008, 62, 88-96.
13. Zheng, S., Hoos, L., Cook J. és mtsai: Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol., 2008, 584, 118-124.
14. Hughes, E. A, Tracey, I., Singhal, S. és mtsa: Unexpected benefi cal effect in the use of ezetimibe in non-alcoholic fatty liver disease. Med. Hypothesis., 2006, 67, 1463-1464.
15. Scharnagl, H., Schinker, R., Gierens, H és mtsai: Effect of atorvas-tatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem. Pharmacol., 2001, 62, 1545-1555.
16. Ishikawa, M., Namiki, A., Kubota, T. és mtsai: Effect of pravas-tatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Inern. Med., 2006, 45, 51-55.
17. Ábel T., Fehér J.: A nem alkoholos zsirmáj és a sziv-ér rendszeri kockázat. Orv. Hetil., 2008, 149, 1299-1305.
18. Sugiyama, S., Fukushima, H., Kugiyama, K. és mtsai: Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis, 2007, 194, e43-e51.
19. Yano, M., Matsumura, T., Senokuchi, T. és mtsai: Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase and p38 mitogen-activated protein kinase-dependent cyclooxigenase-2 expression in mac-rophages. Circ. Res., 2007, 100, 1442-1451.
20. Freeman, D. J., Norrie, J., Sattar, N. és mtsai: Pravastatin and the development of diabetes mellitus: evidence for protective treatment effect in the West Scotland Coronary Prevention Study. Circulation, 2001, 103, 357-362.
21. Hui, J. M., Hodge, A., Farrel, G. C. és mtsai: Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology, 2004, 40, 46-54.
22. Jasinska, M., Owczarek, J., Orszulak-Michalak, D.: Statins: a new insight into their mechanisms of action and consequent pleiotro-pic effects. Pharmacol. Rep., 2007, 59, 483-499.
23. Sanguino, E., Roglans, N., Alegre, M. és mtsai: Atorvastatin reverses age-related reduction in hepatic PPARalpha and HNF-4. Br. J. Pharmacol., 2005, 145, 853-861.
24. Assy, N., Grozovski, M., Bersudsky, I. és mtsai: Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J. Gastroenterol., 2006, 12, 4369-4376.
25. Davie, J. P., Scott, C., Oishi, K. és mtsai: Inactivation of NPCIL1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem., 2005, 280, 12710-12720.